Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 ant… Read more
Akari Therapeutics PLC (AKTX) - Net Assets
Latest net assets as of September 2025: $22.69 Million USD
Based on the latest financial reports, Akari Therapeutics PLC (AKTX) has net assets worth $22.69 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($45.38 Million) and total liabilities ($22.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $22.69 Million |
| % of Total Assets | 50.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | 136.87% |
| 10-Year Change | -54.37% |
| Growth Volatility | 287.35 |
Akari Therapeutics PLC - Net Assets Trend (2010–2024)
This chart illustrates how Akari Therapeutics PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Akari Therapeutics PLC (2010–2024)
The table below shows the annual net assets of Akari Therapeutics PLC from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $22.23 Million | +9806.99% |
| 2023-12-31 | $-229.00K | -112.79% |
| 2022-12-31 | $1.79 Million | -67.76% |
| 2021-12-31 | $5.55 Million | -40.81% |
| 2020-12-31 | $9.38 Million | +144.64% |
| 2019-12-31 | $3.84 Million | -71.32% |
| 2018-12-31 | $13.38 Million | -33.05% |
| 2017-12-31 | $19.98 Million | -41.42% |
| 2016-12-31 | $34.10 Million | -30.00% |
| 2015-12-31 | $48.72 Million | +903.91% |
| 2014-12-31 | $4.85 Million | -16.53% |
| 2013-12-31 | $5.81 Million | +273.04% |
| 2012-12-31 | $-3.36 Million | -35.21% |
| 2011-12-31 | $-2.48 Million | -22.49% |
| 2010-12-31 | $-2.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Akari Therapeutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23662063700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.32 Million | 23.93% |
| Other Comprehensive Income | $-738.00K | -3.32% |
| Other Components | $264.90 Million | 1191.69% |
| Total Equity | $22.23 Million | 100.00% |
Akari Therapeutics PLC Competitors by Market Cap
The table below lists competitors of Akari Therapeutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GREEN360 Technologies Ltd
AU:GT3
|
$16.96 Million |
|
Ibraco Bhd
KLSE:5084
|
$16.96 Million |
|
Hipay Group SA
PA:ALHYP
|
$16.97 Million |
|
Origin Materials Inc
NASDAQ:ORGN
|
$16.97 Million |
|
Orecap Invest Corp.
V:OCI
|
$16.96 Million |
|
Logansport Financial Corp
OTCQB:LOGN
|
$16.96 Million |
|
ANSWEAR.COM SA ZY-05
F:90Z
|
$16.96 Million |
|
Uttam Sugar Mills Limited
NSE:UTTAMSUGAR
|
$16.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akari Therapeutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -229,000 to 22,229,000, a change of 22,458,000.
- Net loss of 19,791,000 reduced equity.
- New share issuances of 11,815,000 increased equity.
- Other comprehensive income decreased equity by 51,892,000.
- Other factors increased equity by 82,326,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.79 Million | -89.03% |
| Share Issuances | $11.81 Million | +53.15% |
| Other Comprehensive Income | $-51.89 Million | -233.44% |
| Other Changes | $82.33 Million | +370.35% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Akari Therapeutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $-15253.27 | $0.22 | x |
| 2011-12-31 | $-18684.21 | $0.22 | x |
| 2012-12-31 | $-27096.77 | $0.22 | x |
| 2013-12-31 | $27685.71 | $0.22 | x |
| 2014-12-31 | $24510.10 | $0.22 | x |
| 2015-12-31 | $114365.08 | $0.22 | x |
| 2016-12-31 | $57997.53 | $0.22 | x |
| 2017-12-31 | $1.60 | $0.22 | x |
| 2018-12-31 | $16931.65 | $0.22 | x |
| 2019-12-31 | $4192.35 | $0.22 | x |
| 2020-12-31 | $5943.20 | $0.22 | x |
| 2021-12-31 | $2588.34 | $0.22 | x |
| 2022-12-31 | $573.85 | $0.22 | x |
| 2023-12-31 | $-46.79 | $0.22 | x |
| 2024-12-31 | $1861.10 | $0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akari Therapeutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.27x
- Recent ROE (-89.03%) is above the historical average (-180.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-472.13K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.87 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.10 Million |
| 2013 | -62.26% | 0.00% | 0.00x | 1.35x | $-4.20 Million |
| 2014 | -198.80% | 0.00% | 0.00x | 1.34x | $-10.13 Million |
| 2015 | -93.02% | 0.00% | 0.00x | 1.43x | $-50.19 Million |
| 2016 | -53.20% | 0.00% | 0.00x | 1.35x | $-21.55 Million |
| 2017 | -139.77% | 0.00% | 0.00x | 1.45x | $-29.92 Million |
| 2018 | -149.15% | 0.00% | 0.00x | 1.23x | $-21.29 Million |
| 2019 | -439.16% | 0.00% | 0.00x | 2.69x | $-17.23 Million |
| 2020 | -182.02% | 0.00% | 0.00x | 1.56x | $-18.02 Million |
| 2021 | -313.69% | 0.00% | 0.00x | 2.10x | $-17.98 Million |
| 2022 | -990.95% | 0.00% | 0.00x | 7.72x | $-17.93 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.99 Million |
| 2024 | -89.03% | 0.00% | 0.00x | 2.27x | $-22.01 Million |
Industry Comparison
This section compares Akari Therapeutics PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akari Therapeutics PLC (AKTX) | $22.69 Million | 0.00% | 1.00x | $16.96 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |